Search Results 861-870 of 17139 for monoclonal antibody

  1. Diseases and Conditions that Start with M - Mayo Clinic

    Monoclonal gammopathy of undetermined significance (MGUS) ... MOG antibody-associated disorder. See. Myelin ... Monoclonal gammopathy of undetermined significance ( ...

  2. A Study of SC‑004 in Subjects With Advanced Solid Tumors - Mayo Clinic

    Chemotherapy, small molecule inhibitors, radiation, and/or other investigational anticancer agents (excluding investigational monoclonal antibodies): within 2 ...

  3. Translational Science - 2020 Archives - Mayo Clinic News Network

    Science Saturday: COVID-19 experimental antibody treatment reaches patients ... Convalescent Plasma: A Therapy for COVID-19? Kate Ledger. April 6, 2020. Science ...

  4. Role of Immunity in Efficacy of Chemotherapy Plus Trastuzumab - Mayo Clinic

    The purpose of this study is to evaluate T cell and antibody immunity in patients with HER2+ breast cancer who will receive trastuzumab with standard ...

  5. MEDI5395 Advanced Solid Tumors - Mayo Clinic

    At least 28 days must have elapsed since non-immunotherapy monoclonal antibody treatment (for example trastuzumab, cetuximab, bevacizumab, or panitumumab); ...

  6. Creation of PLACENTA/Serum Repository Database: Autoimmunity from Mother To Baby Study - Mayo Clinic

    The purpose of the study is to learn more about autoimmunity and potential mother to baby transmission of pathogenic antibodies. The collected research ...

  7. Phase 1a/​1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers - Mayo Clinic

    * Treatment with a monoclonal antibody, or any other anticancer agent (including biologic, experimental, or hormonal therapy) investigational or otherwise ...

  8. A Study of Pembrolizumab Alone as Therapy for Metastatic Triple-Negative Breast Cancer - Mayo Clinic

    Prior anti-cancer monoclonal antibody (mAb) therapy for direct anti-neoplastic treatment within 4 weeks prior to study Day 1; Prior chemotherapy, targeted ...

  9. Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma - Mayo Clinic

    Participation eligibility · Received any prior monoclonal antibody against CTLA-4, programmed cell death 1 (PD1) or programmed cell death 1 ligand 1 (PD-L1); ...

  10. Inotuzumab Ozogamicin in Treating Younger Patients With Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia - Mayo Clinic

    Immunotoxins, such as inotuzumab ozogamicin, are antibodies linked to a ... monoclonal antibody with the exception of blinatumomab; patients must have ...